{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:42:50Z","timestamp":1792896170631,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hormonal agents administered for metastatic castration-resistant prostate cancer (mCRPC) may lead to osteoporosis, skeletal events, reduced quality of life, and even reduced overall survival (OS). Bone-modifying agents may prevent those events but their effect on cancer-control outcomes remains uncertain. Relying on our institutional tertiary-care database, we explored the effect of bone-modifying agents (bisphosphonates such as zoledronic acid and denosumab) on OS and progression-free survival in patients with mCRPC with at least 1 bone metastasis using Kaplan-Meyer estimates and Cox regression models. Of 420 patients with mCRPC, 60% received bone-modifying agents who were younger (68 vs 69\u00a0years), with more systemic treatment lines for mCRPC (3 vs 2), and a higher proportion of initial de novo metastatic disease (72% vs 62%, all p \u2264 .04) than patients without bone-modifying agents. In progression-free survival analyses, no significant differences were observed between both groups. In OS analyses, significant median OS differences were observed in favor of patients with bone-modifying agents (58 vs 45\u00a0months; hazard ratio [HR]: 0.66), even after multivariable adjustment (HR: 0.37; both p \u2264 .01). In bone-modifying agent\u2013stratified analyses, 57% received denosumab vs 43% bisphosphonates, with a significantly higher rate of Eastern Cooperative Oncology Group status of \u22652 in the bisphosphonates group. In progression-free and OS analyses, no significant differences were observed between bisphosphonates and denosumab patients, with numerically better results in progression-free survival analysis for denosumab after adjusting for covariates. The cumulative rate of osteonecrosis of the jaw at any treatment time was 12% in both groups and significantly decreased over time. Real-world data suggest a relatively low administration rate of bone-modifying agents in patients with osseous mCRPC. However, real-world data also suggest an OS benefit when bone-modifying agents are used, even after controlling for possible confounding patient and tumor characteristics.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziae157","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T12:38:52Z","timestamp":1732624732000},"source":"Crossref","is-referenced-by-count":2,"title":["Administration and cancer-control outcomes of bone-modifying agents in real-world patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4338-0889","authenticated-orcid":false,"given":"Mike","family":"Wenzel","sequence":"first","affiliation":[{"name":"Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main , Frankfurt , 63010,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Hoeh","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main , Frankfurt , 63010,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Humke","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main , Frankfurt , 63010,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Welte","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main , Frankfurt , 63010,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Cano Garcia","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main , Frankfurt , 63010,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Siech","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main , Frankfurt , 63010,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[{"name":"Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montr\u00e9al Health Center , Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I","family":"Karakiewcz","sequence":"additional","affiliation":[{"name":"Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montr\u00e9al Health Center , Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[{"name":"Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf , Hamburg ,","place":["Germany"]},{"name":"Department of Urology, University Hospital Hamburg-Eppendorf , Hamburg ,","place":["Germany"]},{"name":"Department of Urology, Koc University Hospital , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Steuber","sequence":"additional","affiliation":[{"name":"Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[{"name":"Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Traumann","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main , Frankfurt , 63010,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K H","family":"Chun","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main , Frankfurt , 63010,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mandel","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main , Frankfurt , 63010,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"issue":"2","key":"2024121508000162000_ref1","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.euo.2023.01.014","article-title":"Metastatic sites\u2019 location and impact on patient management after the introduction of prostate-specific membrane antigen positron emission tomography in newly diagnosed and biochemically recurrent prostate cancer: a critical review","volume":"6","author":"Mattana","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"2024121508000162000_ref2","doi-asserted-by":"publisher","first-page":"100575","DOI":"10.1016\/j.esmoop.2022.100575","article-title":"Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Maiorano","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"2024121508000162000_ref3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur Urol"},{"key":"2024121508000162000_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.03.024","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume","author":"Hoeh","journal-title":"Eur Urol Focus"},{"key":"2024121508000162000_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2021.04.003","article-title":"Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis","author":"Wenzel","journal-title":"Eur Urol Focus"},{"issue":"2","key":"2024121508000162000_ref6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"2024121508000162000_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2022.08.007","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis [published online ahead of print September 1, 2022]","author":"Mandel","journal-title":"Eur Urol Focus"},{"issue":"32","key":"2024121508000162000_ref8","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024121508000162000_ref9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"2024121508000162000_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.08.007","article-title":"Prostate-specific antigen nadir and cancer-control outcomes in real-world apalutamide-treated metastatic hormone-sensitive prostate cancer patients: a single-center analysis","author":"Wenzel","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2024121508000162000_ref11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.euros.2024.06.010","article-title":"Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients","volume":"66","author":"Wenzel","year":"2024","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"2024121508000162000_ref12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/ncpuro0995","article-title":"Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?","volume":"5","author":"Higano","year":"2008","journal-title":"Nat Clin Pract Urol"},{"issue":"4","key":"2024121508000162000_ref13","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J Urol"},{"issue":"2","key":"2024121508000162000_ref14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2024121508000162000_ref15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"2024121508000162000_ref16","article-title":"EAU guidelines on prostate cancer","author":"Mottet","year":"2019"},{"issue":"9768","key":"2024121508000162000_ref17","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"53","key":"2024121508000162000_ref18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2015.09.011","article-title":"Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics","volume":"53","author":"Lipton","year":"1990","journal-title":"Eur J Cancer"},{"issue":"8","key":"2024121508000162000_ref19","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"2024121508000162000_ref20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41391-022-00573-y","article-title":"Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer","volume":"26","author":"Mitchell","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10024","key":"2024121508000162000_ref21","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"2024121508000162000_ref22","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"157","key":"2024121508000162000_ref23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ejca.2021.06.005","article-title":"Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer\u2014an Australian multi-Centre observational study","volume":"157","author":"Anton","year":"1990","journal-title":"Eur J Cancer"},{"issue":"3","key":"2024121508000162000_ref24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"2024121508000162000_ref25","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/oncolo\/oyae036","article-title":"Real-world evaluation of primary versus secondary prevention of skeletal-related events in metastatic castration-resistant prostate cancer","volume":"29","author":"Phillips","year":"2024","journal-title":"Oncologist"},{"issue":"19","key":"2024121508000162000_ref26","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2024121508000162000_ref27","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00520-021-06340-4","article-title":"Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate","volume":"30","author":"Miyashita","year":"2022","journal-title":"Support Care Cancer"},{"key":"2024121508000162000_ref28","doi-asserted-by":"publisher","first-page":"107417","DOI":"10.1016\/j.lungcan.2023.107417","article-title":"High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors","volume":"186","author":"Manglaviti","year":"2023","journal-title":"Lung Cancer"},{"issue":"4","key":"2024121508000162000_ref29","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00774-021-01207-4","article-title":"Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study","volume":"39","author":"Sakai","year":"2021","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"2024121508000162000_ref30","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.oooo.2020.12.018","article-title":"Influence of prostate cancer status on the prevalence of medication-related osteonecrosis of the jaw","volume":"131","author":"Yasui","year":"2021","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"17","key":"2024121508000162000_ref31","doi-asserted-by":"publisher","first-page":"18317","DOI":"10.1002\/cam4.6429","article-title":"A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with denosumab","volume":"12","author":"Bracchi","year":"2023","journal-title":"Cancer Med"},{"issue":"10","key":"2024121508000162000_ref32","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.jcms.2016.07.026","article-title":"Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid\u2014a prospective study over 6 years","volume":"44","author":"M\u00fccke","year":"2016","journal-title":"J Craniomaxillofac Surg"},{"issue":"12","key":"2024121508000162000_ref33","doi-asserted-by":"publisher","first-page":"CD013020","DOI":"10.1002\/14651858.CD013020.pub2","article-title":"Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis","author":"Jakob","year":"2020","journal-title":"Cochrane Database Syst Rev"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziae157\/60816871\/ziae157.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/1\/ziae157\/61182597\/ziae157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/1\/ziae157\/61182597\/ziae157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T08:00:09Z","timestamp":1734249609000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziae157\/7908814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziae157","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,11,26]]},"article-number":"ziae157"}}